Aquestive Therapeutics Continues To Expect FY24 Total Revenue Of $48M-$51M, Est $50.214M
Portfolio Pulse from Benzinga Newsdesk
Aquestive Therapeutics projects FY24 revenue to be between $48M-$51M, aligning with an estimate of $50.214M. As of March 31, 2024, cash and equivalents stood at $95.2M, with an extended cash runway into 2026 following a $77.5M underwritten public offering.
May 07, 2024 | 10:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aquestive Therapeutics expects FY24 revenue of $48M-$51M, closely matching the $50.214M estimate. With $95.2M in cash and a successful $77.5M offering, its financial stability is reinforced.
The company's projection of FY24 revenue aligns with analyst estimates, indicating confidence in its financial outlook. The successful capital raise through a public offering, coupled with a strong cash position, suggests a positive short-term impact on AQST's stock price, as it demonstrates financial health and the ability to sustain operations and growth into 2026.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100